Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation

Philip G. Thomas, Kenneth J. Woodside, Jacqueline A. Lappin, Smita Vaidya, Srinivasan Rajaraman, Kristene Gugliuzza

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Immunosuppression for immunologically high-risk renal transplant patients usually involves antithymocyte globulin induction with triple drug maintenance therapy. Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression. In this prospective, open-label, randomized, controlled trial, we enrolled 21 high immunological risk patients (i.e., panel reactive antibody >20% or previous transplant). Patients received either single-dose alemtuzumab given before graft reperfusion, with tacrolimus monotherapy, or four doses of Thymoglobulin® with tacrolimus, mycophenolate, and steroids. Median follow-up was 377 days. One patient in the Thymoglobulin group who suffered primary graft nonfunction died. One-year cumulative graft survival was 85.7% for the alemtuzumab group and 87.5% for the Thymoglobulin group. Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes. Infection rates were similar. Early results of this ongoing study indicate that a tolerogenic protocol with alemtuzumab induction and tacrolimus maintenance monotherapy is safe in immunologically high-risk renal transplant patients.

Original languageEnglish (US)
Pages (from-to)1509-1512
Number of pages4
JournalTransplantation
Volume83
Issue number11
DOIs
StatePublished - Jun 2007

Fingerprint

Tacrolimus
Kidney Transplantation
Transplants
Immunosuppression
Maintenance
Kidney
Antibodies, Monoclonal, Humanized
Antilymphocyte Serum
Graft Survival
Reperfusion
alemtuzumab
Anti-Idiotypic Antibodies
Randomized Controlled Trials
Steroids
Drug Therapy
thymoglobulin
Antibodies
Infection

Keywords

  • Alemtuzumab
  • Antithymocyte globulin
  • Campath 1H
  • High panel reactive antibody
  • Prospective randomized controlled trial
  • Renal transplantation
  • Tacrolimus
  • Thymoglobulin
  • Tolerogenic induction
  • Transplant induction

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. / Thomas, Philip G.; Woodside, Kenneth J.; Lappin, Jacqueline A.; Vaidya, Smita; Rajaraman, Srinivasan; Gugliuzza, Kristene.

In: Transplantation, Vol. 83, No. 11, 06.2007, p. 1509-1512.

Research output: Contribution to journalArticle

Thomas, Philip G. ; Woodside, Kenneth J. ; Lappin, Jacqueline A. ; Vaidya, Smita ; Rajaraman, Srinivasan ; Gugliuzza, Kristene. / Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. In: Transplantation. 2007 ; Vol. 83, No. 11. pp. 1509-1512.
@article{e61971ba03ef4625b8208ce045773116,
title = "Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation",
abstract = "Immunosuppression for immunologically high-risk renal transplant patients usually involves antithymocyte globulin induction with triple drug maintenance therapy. Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression. In this prospective, open-label, randomized, controlled trial, we enrolled 21 high immunological risk patients (i.e., panel reactive antibody >20{\%} or previous transplant). Patients received either single-dose alemtuzumab given before graft reperfusion, with tacrolimus monotherapy, or four doses of Thymoglobulin{\circledR} with tacrolimus, mycophenolate, and steroids. Median follow-up was 377 days. One patient in the Thymoglobulin group who suffered primary graft nonfunction died. One-year cumulative graft survival was 85.7{\%} for the alemtuzumab group and 87.5{\%} for the Thymoglobulin group. Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes. Infection rates were similar. Early results of this ongoing study indicate that a tolerogenic protocol with alemtuzumab induction and tacrolimus maintenance monotherapy is safe in immunologically high-risk renal transplant patients.",
keywords = "Alemtuzumab, Antithymocyte globulin, Campath 1H, High panel reactive antibody, Prospective randomized controlled trial, Renal transplantation, Tacrolimus, Thymoglobulin, Tolerogenic induction, Transplant induction",
author = "Thomas, {Philip G.} and Woodside, {Kenneth J.} and Lappin, {Jacqueline A.} and Smita Vaidya and Srinivasan Rajaraman and Kristene Gugliuzza",
year = "2007",
month = "6",
doi = "10.1097/01.tp.0000263344.53000.a1",
language = "English (US)",
volume = "83",
pages = "1509--1512",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation

AU - Thomas, Philip G.

AU - Woodside, Kenneth J.

AU - Lappin, Jacqueline A.

AU - Vaidya, Smita

AU - Rajaraman, Srinivasan

AU - Gugliuzza, Kristene

PY - 2007/6

Y1 - 2007/6

N2 - Immunosuppression for immunologically high-risk renal transplant patients usually involves antithymocyte globulin induction with triple drug maintenance therapy. Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression. In this prospective, open-label, randomized, controlled trial, we enrolled 21 high immunological risk patients (i.e., panel reactive antibody >20% or previous transplant). Patients received either single-dose alemtuzumab given before graft reperfusion, with tacrolimus monotherapy, or four doses of Thymoglobulin® with tacrolimus, mycophenolate, and steroids. Median follow-up was 377 days. One patient in the Thymoglobulin group who suffered primary graft nonfunction died. One-year cumulative graft survival was 85.7% for the alemtuzumab group and 87.5% for the Thymoglobulin group. Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes. Infection rates were similar. Early results of this ongoing study indicate that a tolerogenic protocol with alemtuzumab induction and tacrolimus maintenance monotherapy is safe in immunologically high-risk renal transplant patients.

AB - Immunosuppression for immunologically high-risk renal transplant patients usually involves antithymocyte globulin induction with triple drug maintenance therapy. Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression. In this prospective, open-label, randomized, controlled trial, we enrolled 21 high immunological risk patients (i.e., panel reactive antibody >20% or previous transplant). Patients received either single-dose alemtuzumab given before graft reperfusion, with tacrolimus monotherapy, or four doses of Thymoglobulin® with tacrolimus, mycophenolate, and steroids. Median follow-up was 377 days. One patient in the Thymoglobulin group who suffered primary graft nonfunction died. One-year cumulative graft survival was 85.7% for the alemtuzumab group and 87.5% for the Thymoglobulin group. Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes. Infection rates were similar. Early results of this ongoing study indicate that a tolerogenic protocol with alemtuzumab induction and tacrolimus maintenance monotherapy is safe in immunologically high-risk renal transplant patients.

KW - Alemtuzumab

KW - Antithymocyte globulin

KW - Campath 1H

KW - High panel reactive antibody

KW - Prospective randomized controlled trial

KW - Renal transplantation

KW - Tacrolimus

KW - Thymoglobulin

KW - Tolerogenic induction

KW - Transplant induction

UR - http://www.scopus.com/inward/record.url?scp=34250658405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250658405&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000263344.53000.a1

DO - 10.1097/01.tp.0000263344.53000.a1

M3 - Article

C2 - 17565326

AN - SCOPUS:34250658405

VL - 83

SP - 1509

EP - 1512

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 11

ER -